A trial of pasireotide for people who have symptoms of carcinoid syndrome that are not controlled with other drugs (SIG-NET)

Cancer type:

Neuroendocrine tumour (NET)




Phase 3

This trial looked at a drug called pasireotide to see if it controlled symptoms of carcinoid syndrome.

Neuroendocrine tumours (NETs) are a rare group of cancers that make and release hormones Open a glossary item. They are normally found in the digestive system Open a glossary item. The most common type of NET is called carcinoid.

Carcinoid tumours can spread to other parts of the body such as the liver, lymph nodes Open a glossary item or lungs. If a carcinoid tumour spreads to the liver, it often produces a hormone called serotonin (also known as 5HT) and causes symptoms such as flushing, wheezing, diarrhoea and an irregular heartbeat (palpitations). This is known as carcinoid syndrome.

Doctors may treat carcinoid syndrome with drugs called somatostatin analogues. These drugs can help, but do not control diarrhoea or flushing.

In this trial, researchers looked at a somatostatin analogue called pasireotide. They compared it with another drug called octreotide. Octreotide is already used to treat carcinoid syndrome but in this trial, people had a higher dose than doctors usually give.

The aim of the trial was to see which of these 2 treatments was better for people who had symptoms of carcinoid syndrome that were not controlled with other drugs.

Summary of results

The trial team found that pasireotide was similar to octreotide for controlling the symptoms of carcinoid syndrome.

This was a phase 3 trial. It recruited 110 people. It was a randomised trial. The people taking part were put into treatment groups by a computer. Neither they nor their doctor were able to decide which group they were in.

The 2 groups were

  • 53 people who had pasireotide
  • 57 people who had octreotide

After 6 months of treatment the researchers looked at how many people had their symptoms controlled. They found that it was

  • 21 out of every 100 people (21%) who had pasireotide
  • 27 out of every 100 people (27%) who had octreotide

The most common symptoms in both groups were diarrhoea and tummy (abdominal) pain. Some people who had pasireotide also had high blood sugar levels but most of those who had octreotide didn’t.

After these results the team decided to close the trial early.

The trial team concluded that pasireotide was similar to octreotide in controlling symptoms of carcinoid syndrome. They also said that another phase 3 trial with a larger number of people was needed to make clearer what role pasireotide might have as treatment for carcinoid syndrome.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Was Mansoor

Supported by

Experimental Cancer Medicine Centre (ECMC)
NET Patient Foundation
National Institute for Health Research Cancer Research Network (NCRN)

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:


Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page